Related Experiment Video
Updated: Jan 10, 2026

Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test
Published on: November 13, 2016
C-peptide Index under Non-fasting Conditions Can Predict the Likelihood of Future Insulin Therapy in Outpatients with
Yuichiro Iwamoto1, Tomohiko Kimura1, Yuichi Morimoto2
1Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Japan.
Abstract:
Objective This study aimed to develop a clinical model in which the C-peptide index (CPI) under non-fasting conditions can predict future insulin therapy in patients with type 2 diabetes mellitus (T2DM). Methods This was a single-center retrospective study. We analyzed the correlation between non-fasting CPI and future insulin therapy in 464 patients who T2DM not receive insulin therapy who attended our clinic and were evaluated for non-fasting CPI on an outpatient basis. We used machine learning as an adjunct method to create a clinical model to predict future insulin therapy. Results At the end of the observation period, 22 participants remained on insulin therapy (continuous insulin therapy group: CIG), and 442 were not on insulin therapy (without insulin therapy group: WIG). HbA1c and serum creatinine (Cre) were significantly higher in the CIG than in the WIG (p<0.001 and p=0.045, respectively). The non-fasting CPI was lower in the CIG than in the WIG (p<0.001). The cutoff value of non-fasting CPI to predict the need of future insulin therapy was 1.62 (sensitivity 40.9%, specificity 90.7%), and the cutoff value to indicate the low possibility of future insulin therapy was 3.11 (sensitivity 90.1%, specificity 48.9%). A clinical model was created to predict future insulin therapy by machine learning using the Easy Ensemble Classifier method with non-fasting CPI, HbA1c, and Cre as features (accuracy, 78.5%; area under the ROC curve 0.86, false positive rate, 18.2%; false negative rate, 22.2%). Conclusion CPI under non-fasting conditions can predict the likelihood of future insulin therapy in outpatients with T2DM.
More Related Videos
Related Concept Videos
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Dipeptidyl Peptidase 4 Inhibitors
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
Insulin and C-peptide are...
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Cell Specific Gene Expression
Diabetes Mellitus: Type 2 and Gestational

